# Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer

> **NCT00003251** · PHASE1,PHASE2 · UNKNOWN · sponsor: **University of Illinois at Chicago** · enrollment: 46 (estimated)

## Conditions studied

- Drug/Agent Toxicity by Tissue/Organ
- Head and Neck Cancer
- Radiation Toxicity

## Interventions

- **DRUG:** amifostine trihydrate
- **DRUG:** cisplatin
- **DRUG:** paclitaxel
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00003251
- **Lead sponsor:** University of Illinois at Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1997-12
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2013-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003251, "Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00003251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*